Randomized phase III trial of neoadjuvant therapy in patients with palpable and operable breast cancer evaluating the effect on pathologic complete response (pCR) of adding capecitabine or gemcitabine to docetaxel when administered before AC with or without bevacizumab and correlative science studies attempting to identify predictors of high likelihood for pCR with each of the regimens

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT00408408?term=NSABP-B-40&rank=1

2. Intervention

   Capecitabine

3. Intervention

   Cyclophosphamide

4. Intervention

   Docetaxel

5. Intervention

   Doxorubicin hydrochloride

6. Intervention

   Gemcitabine hydrochloride

7. Intervention

   Bevacizumab

8. Intervention

   Conventional surgery

9. Additional Topic(s)

   Antineoplastic combined chemotherapy protocols

10. Resource Description

    Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Bevacizumab may also stop the growth of breast cancer by blocking blood flow to the tumor. Giving chemotherapy and bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving bevacizumab after surgery may kill any tumor cells that remain after surgery. It is not yet known which chemotherapy regimen is more effective with or without bevacizumab in treating breast cancer. This randomized phase III trial is studying six different chemotherapy regimens to compare how well they work with or without bevacizumab in treating women with stage I, stage II, or stage IIIA breast cancer that can be removed by surgery.

11. Contact

    Berenberg, Jeffrey

12. PI

    Berenberg, Jeffrey

13. Topic

    breast cancer

14. Study Population

    Females age 18 and older with histologically confirmed invasive adenocarcinoma of the breast.

15. Website(s)

    http://www.cancer.gov/clinicaltrials/search/view?cdrid=515432&version=healthprofessional

16. Funded by

    National Surgical Adjuvant Breast and Bowel Project

17. Phase

    Phase 3 clinical trial

18. Performed by

    Clinical Protocol & Data Management Shared Resource